Z01 BC010666/ImNIH/Intramural NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2008	1
2009	3
2010	2
2011	6
2012	2
2018	1
2024	0

1

Poxviral vectors for cancer immunotherapy.

Kim JW, Gulley JL. Kim JW, et al. Expert Opin Biol Ther. 2012 Apr;12(4):463-78. doi: 10.1517/14712598.2012.668516. Expert Opin Biol Ther. 2012. PMID: 22413824 Free PMC article. Review.

2

Therapeutic prostate cancer vaccines: a review of the latest developments.

Mohebtash M, Madan RA, Gulley JL, Arlen PM. Mohebtash M, et al. Curr Opin Investig Drugs. 2008 Dec;9(12):1296-301. Curr Opin Investig Drugs. 2008. PMID: 19037836 Free PMC article. Review.

3

Current perspectives in prostate cancer vaccines.

Arlen PM, Gulley JL. Arlen PM, et al. Anticancer Agents Med Chem. 2009 Dec;9(10):1052-7. doi: 10.2174/187152009789735062. Anticancer Agents Med Chem. 2009. PMID: 19719454 Free PMC article. Review.

4

Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.

Madan RA, Gulley JL. Madan RA, et al. Expert Rev Vaccines. 2011 Feb;10(2):141-50. doi: 10.1586/erv.10.173. Expert Rev Vaccines. 2011. PMID: 21332262 Free PMC article. Review.

5

Cancer vaccines: current directions and perspectives in prostate cancer.

Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM. Mohebtash M, et al. Curr Opin Mol Ther. 2009 Feb;11(1):31-6. Curr Opin Mol Ther. 2009. PMID: 19169957 Free PMC article. Review.

6

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Madan RA, et al. Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Expert Opin Investig Drugs. 2009. PMID: 19548854 Free PMC article. Review.

7

The current and emerging role of immunotherapy in prostate cancer.

Madan RA, Gulley JL. Madan RA, et al. Clin Genitourin Cancer. 2010 Dec 1;8(1):10-6. doi: 10.3816/CGC.2010.n.002. Clin Genitourin Cancer. 2010. PMID: 21208850 Free PMC article. Review.

8

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Kelly RJ, Gulley JL, Giaccone G. Kelly RJ, et al. Clin Lung Cancer. 2010 Jul 1;11(4):228-37. doi: 10.3816/CLC.2010.n.029. Clin Lung Cancer. 2010. PMID: 20630824 Free PMC article. Review.

9

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. Madan RA, et al. Expert Rev Vaccines. 2011 Jun;10(6):743-53. doi: 10.1586/erv.11.70. Expert Rev Vaccines. 2011. PMID: 21692697 Free PMC article. Review.

10

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Merino MJ, Pinto PA, Moreno V, Gil S, Schlom J, Gulley JL. Merino MJ, et al. Hum Pathol. 2018 Aug;78:72-78. doi: 10.1016/j.humpath.2018.04.013. Epub 2018 Apr 30. Hum Pathol. 2018. PMID: 29709495 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year